Immuno-oncology (Hu)MAbs

OCR Number: OCR 6325

Description:

- Neutralizing antibodies to OCR6325 are potential immune therapeutic agents to treat cancers that overexpress a novel soluble target expressed in epithelia (left figure).
- CDRs are transferable for humanization.
- \textit{In vivo} small animal studies show that neutralization of the soluble protein target significantly reduces tumor burden in established tumors (both figures).
- OCR6325 is a promising immunotherapeutic target for treating epithelial cancers.
- Antibodies are to conserved epitope in human/mouse.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{tumor_size.png}
\caption{Xenograft Model}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{genetic_model.png}
\caption{Genetic Model}
\end{figure}

Licensing Contact: David Lewin
david.lewin@yale.edu